CD19 and neoplasm: The “on-target, off-tumor toxicity” of CD19-directed CAR-T cells, such as B-cell dysplasia and hypogammaglobulinemia, can be reversed after a few months of CAR-T cell infusion because of the existence of HSPC and plasma cells.